SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Deciphering METAstasis of lung cancer to BRAIN and developing new therapeutic approaches via a human metastatic cascade platform

META-BRAIN aims to develop a human-based in vitro model to study cancer brain metastasis, the role of the blood-brain barrier, and create targeted drug delivery systems for effective treatment.

Subsidie
€ 1.500.000
2024

Projectdetails

Introduction

Brain metastases have a poor prognosis and are associated with a high morbidity and mortality rate in cancer patients. The metastatic pathways and the role of the blood-brain barrier (BBB) during metastasis are not known. There is a need to better understand cancer brain metastasis and develop effective therapeutics.

Project Overview

With META-BRAIN, I will create a human-based in vitro platform that spans the entire cancer cell journey from lung to brain and use it to address three key questions:

  1. How does cancer metastasize to the brain?
  2. What is the role of the BBB in cancer metastasis to the brain?
  3. How and when can cancer metastasis be treated?

Model Development

The META-BRAIN will provide answers to these questions by developing a truly physiologically relevant human cell-based model that, for the first time, maps the entire cancer metastasis cascade. This model can also be used to study novel target proteins at the blood-tumor barrier (BTB). Additionally, this model will be used to develop novel shuttle systems for drug delivery to the brain.

Objectives

By integrating state-of-the-art technologies from life sciences and engineering, META-BRAIN has three main objectives:

  1. Develop an in vitro model that recapitulates the metastatic cascade with in vivo-like morphology and function to study how cancer metastasizes to the brain.
  2. Investigate the role of extracellular vesicle (EV) and circulating tumor cell (CTC) migration events with a focus on their interactions with brain endothelia.
  3. Identify novel target proteins specific to cancerous brain and develop novel nano-shuttle systems targeting these proteins to deliver therapeutics to the brain.

Conclusion

In summary, META-BRAIN will lead the way in the development of physiologically relevant models for other brain-invasive metastatic cancers. It will open new avenues for the development of therapeutic and diagnostic approaches and pave the way for nano-shuttle formulations specifically designed to overcome the BBB and BTB.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.500.000
Totale projectbegroting€ 1.500.000

Tijdlijn

Startdatum1-8-2024
Einddatum31-7-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • SABANCI UNIVERSITESIpenvoerder

Land(en)

Türkiye

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Creating an orthogonal gate to the brain

This project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer.

ERC Starting...€ 1.499.136
2023
Details

Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD

The ARACHNID project aims to develop a multiplexed, automated tumor-metastasis-on-a-chip platform to enhance understanding and treatment of cancer metastasis, starting with pediatric tumors.

ERC Proof of...€ 150.000
2024
Details

Mechanobiology of cancer progression

This project aims to develop an innovative in vivo platform to study tumor fibrosis and improve targeted cancer therapies by mimicking the fibrotic microenvironment of breast cancer.

ERC Advanced...€ 2.498.690
2022
Details

Targeting Mfrn2 to Inhibit Metastatic Cancers

This project aims to evaluate a solute carrier transporter as a drug target to inhibit metastatic growth in breast cancer, utilizing patient samples and mouse models for comprehensive analysis.

ERC Proof of...€ 150.000
2023
Details

Decoding and Targeting Treatment-Resistant Metastatic Neuroblastoma

This project aims to develop advanced models to study treatment resistance in neuroblastoma, identify novel therapeutic targets, and validate combination therapies for relapsed cases.

ERC Consolid...€ 2.000.000
2024
Details
ERC Starting...

Creating an orthogonal gate to the brain

This project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer.

ERC Starting Grant
€ 1.499.136
2023
Details
ERC Proof of...

Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD

The ARACHNID project aims to develop a multiplexed, automated tumor-metastasis-on-a-chip platform to enhance understanding and treatment of cancer metastasis, starting with pediatric tumors.

ERC Proof of Concept
€ 150.000
2024
Details
ERC Advanced...

Mechanobiology of cancer progression

This project aims to develop an innovative in vivo platform to study tumor fibrosis and improve targeted cancer therapies by mimicking the fibrotic microenvironment of breast cancer.

ERC Advanced Grant
€ 2.498.690
2022
Details
ERC Proof of...

Targeting Mfrn2 to Inhibit Metastatic Cancers

This project aims to evaluate a solute carrier transporter as a drug target to inhibit metastatic growth in breast cancer, utilizing patient samples and mouse models for comprehensive analysis.

ERC Proof of Concept
€ 150.000
2023
Details
ERC Consolid...

Decoding and Targeting Treatment-Resistant Metastatic Neuroblastoma

This project aims to develop advanced models to study treatment resistance in neuroblastoma, identify novel therapeutic targets, and validate combination therapies for relapsed cases.

ERC Consolidator Grant
€ 2.000.000
2024
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.

EIC Pathfinder€ 5.972.875
2024
Details

3D spheroids derived from single cells for discovering stochastic patterns behind metastasis

3DSecret aims to revolutionize cancer treatment by analyzing single circulating tumor cells using advanced technologies to uncover stochastic patterns driving metastasis and improve diagnosis and prognosis.

EIC Pathfinder€ 2.591.050
2023
Details
EIC Pathfinder

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.

EIC Pathfinder
€ 5.972.875
2024
Details
EIC Pathfinder

3D spheroids derived from single cells for discovering stochastic patterns behind metastasis

3DSecret aims to revolutionize cancer treatment by analyzing single circulating tumor cells using advanced technologies to uncover stochastic patterns driving metastasis and improve diagnosis and prognosis.

EIC Pathfinder
€ 2.591.050
2023
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.